Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

NCT05064358 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

177

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Belantamab mafodotin

Sponsor

GlaxoSmithKline